Allient Q2 2026 Earnings: Record Gross Margin Lifts Profitability

Allient (Nasdaq: ALNT) reported Q2 2026 revenue of $153.8 million, up 10% from $139.6 million a year earlier, while diluted EPS rose to $0.61 from $0.34. For the quarter ended June 30, gross margin reached a record 34.9%, and orders grew substantially faster than revenue, lifting backlog to $298.0 million.

Core earnings data

Reported revenue growth included a favorable $1.3 million currency effect. On the company’s non-GAAP organic basis, which excludes currency and acquisition effects, revenue increased 9.3%.

Profit grew faster than revenue as higher volume, improved product mix and operational improvements under the Simplify to Accelerate NOW initiative expanded margins. Lower interest expense and a lower effective tax rate also supported net income.

Adjusted diluted EPS and adjusted EBITDA are non-GAAP measures. Operating expenses increased to $38.0 million from $34.7 million, but declined slightly as a percentage of revenue to 24.7%. Higher commissions, personnel costs, incentive compensation and sales and marketing expenses accounted for the dollar increase.

Business and market performance

Industrial and Aerospace & Defense produced the fastest growth, while Medical also expanded. Vehicle revenue and distribution-channel sales declined, creating a clear difference between Allient’s growth markets and its weaker powersports and channel exposure.

Sales to U.S. customers represented 54% of revenue, compared with 55% a year earlier, with the remainder generated primarily in Europe, Canada and Asia-Pacific.

Orders outpaced revenue and expanded backlog

Orders reached a record $201.3 million, up 49% year over year and 27% sequentially. Because orders exceeded quarterly revenue, the book-to-bill ratio rose to 1.31x, with the strongest demand improvements coming from Industrial and Aerospace & Defense.

Backlog ended the quarter at $298.0 million, up from $251.0 million at March 31, 2026. Management expects most of the backlog to convert into revenue within three to nine months, making execution and shipment timing important indicators for the second half of 2026 and early 2027.

Working capital investment reduced cash conversion despite higher earnings

The cash-flow figures cover the first six months of 2026 rather than Q2 alone. Six-month operating cash flow fell to $20.1 million from $38.4 million even as six-month net income increased to $15.7 million from $9.2 million. The difference primarily reflected receivables timing and inventory investments intended to support growth and secure critical materials amid supply constraints.

At June 30, trade receivables were $99.8 million, up from $88.8 million at year-end, while inventories increased to $117.9 million from $109.2 million. First-half capital expenditures also rose to $7.1 million from $3.2 million as Allient invested in capacity, technology and productivity. Management expects working capital to normalize as inventory and backlog convert into revenue and cash.

Cash and cash equivalents were $42.1 million at quarter-end. Total debt declined by $4.0 million during Q2 to $173.3 million, while the company-defined leverage ratio improved to 1.63x. Net debt was $131.2 million, and Allient had $162.0 million of unused revolving-credit capacity.

2026 guidance

Allient provided full-year expectations for capital spending, restructuring costs and its effective tax rate. These ranges indicate continued investment in capacity and the Dothan transition while framing the associated cash and expense requirements.

Recent insider transactions

The supplied insider records show that most of the latest activity consisted of stock awards rather than open-market transactions. The clearest sale was General Counsel Ashish Bendre’s disposition of 6,000 shares for $378,000; the transaction alone does not establish an insider view of the company’s prospects.

Risks investors should monitor

• Working-capital pressure: Receivables and inventory absorbed cash during the first half. Delays in converting these assets into sales and collections could keep operating cash flow below earnings.
• Backlog execution and supply constraints: The larger backlog supports revenue visibility, but realizing that benefit depends on production, material availability and shipments occurring within the expected three-to-nine-month period.
• Uneven end-market demand: Vehicle revenue declined because of weaker powersports demand, while distribution sales fell due to variable channel ordering. Continued weakness could offset some growth in Industrial and Aerospace & Defense.
• Restructuring and transition execution: Carryover costs from the Dothan transition remained elevated, and full-year restructuring and realignment costs are expected to reach $2 million to $3 million.
• Higher operating investment: Personnel, incentive compensation, sales and marketing expenses increased with growth. Those costs could weigh on operating leverage if revenue momentum slows.

Summary

Allient’s Q2 2026 results combined double-digit reported revenue growth with record gross margin and faster earnings growth, supported by Industrial, Aerospace & Defense and Medical demand. Record orders and higher backlog strengthen forward revenue visibility, but investors should watch whether backlog and inventory convert into cash as expected, whether current margins hold, and how effectively Allient completes its restructuring and capacity investments.